Melagatran
CAS: 159776-70-2
Ref. 3D-FM25041
1mg | A consultar | ||
2mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar |
Información del producto
- N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycineH-319/68
- Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-
- Glycine, N-[2-[2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-, [S-(R*,S*)]-
- H-319/68
- N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycine
- N-[(1R)-2-{(2S)-2-[(4-carbamimidoylbenzyl)carbamoyl]azetidin-1-yl}-1-cyclohexyl-2-oxoethyl]glycine
Melagatran is a coumarin derivative that acts as a thrombin receptor antagonist. It has been shown to have anti-thrombotic effects in an experimental model of balloon injury and in a vivo model of arterial thrombosis. Melagatran has been shown to significantly inhibit the progression of atherosclerotic lesions when administered orally, without adverse effects on blood coagulation or liver function. This drug may be useful for the prevention or treatment of cardiovascular disease in patients with hepatic impairment. Melagatran is rapidly converted into melagatran in vivo and has no significant pharmacological activity. The drug can be detected by analytical methods such as high performance liquid chromatography (HPLC).
Propiedades químicas
Consulta técnica sobre: 3D-FM25041 Melagatran
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.